A PMCF Investigation on Chronic LU and DFU in Need of Debridement With ChloraSolv®

Terminated

• Conditions: Chronic Leg Ulcer; Chronic Diabetic Foot Ulcer

• Registration Number: NCT04838600
• Lead Sponsor: RLS Global

Brief Summary

This is a single-arm, observational, multicenter PMCF investigation designed to confirm clinical performance and safety of ChloraSolv when exposed to larger population of clinical users. Approximately 65 subjects will be enrolled (calculated dropout range 20%) from at least 6-12 sites in Sweden. Subjects presented with chronic leg ulcers and chronic diabetic foot ulcers in need of debridement will be enrolled and receive application of ChloraSolv per clinical routine at treating site and in accordance with the ChloraSolv Instruction for Use for up to 24 weeks. Subjects will attend a baseline visit to assess eligibility and collect demographic and baseline data and initiate treatment. There will be two follow up visits in the investigation. The first follow up visit will take place at End of Treatment, as based on investigator judgement and clinical routine at the treating site, maximum 24 weeks post baseline per the IFU. After End of Treatment, subjects will continue in the investigation with wound management per clinical routine at the treating sites for 6 weeks. At 6 weeks post End of Treatment, subjects will attend a Follow-up visit to assess safety, wound status and relative change in wound size. Besides confirmation of the clinical performance and safety when used in a larger population the investigation also includes analysis of treatment period duration. Additionally, health economy parameters will be analyzed. The investigation will be monitored to confirm the already known precautions as well as identify new precautions and possible contraindications for the use of the device. Photography of the wound pre and post debridement will be performed to confirm wound size and amount of devitalized tissue in the wound.

Detailed Description

As above

Study Timeline

• Study First Submitted: 2021-04-06
• Study First Submitted QC: 2021-04-08
• Study First Posted: 2021-04-09
• Study Start: 2021-06-07
• Status Verified: 2023-08
• Primary Completion: 2023-11-20
• Study Completion: 2023-11-20
• Last Update Submitted: 2023-11-28
• Last Update Posted: 2023-12-04

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

1. Chronic leg ulcers and chronic diabetic foot ulcers in need of debridement
2. Male or female, 18 years of age and above
3. Able to read and understand the Patient Informed Consent and to provide meaningful written informed consent

Exclusion Criteria

1. Known allergy/hypersensitivity to any of the components of ChloraSolv
2. Renal insufficiency defined as serum creatinine >200 μmol/L
3. Macroangiopathy expected to demand vascular intervention or percutaneous angioplasty performed less than 3 months after start of treatment; toe pressure <30mm Hg
4. Kidney or pancreas transplanted
5. Patient under cortisone treatment >60mg/day
6. Patient treated with chemotherapy or any other immune-inhibiting drugs 12 months before start of treatment
7. Other identified on-going pathologies in the area of wound, such as cancer
8. Pregnancy or breastfeeding
9. Subjects included in other ongoing clinical investigations which could interfere with this investigation, as judged by the investigator
10. Subjects not suitable for the investigation according to the investigator's judgment or other significant medical conditions that the investigator determines could interfere with compliance or investigation assessments.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of clean wound bed at End of Treatment, as assessed by investigator	1 - 24 weeks	When the investigator judges that the wound is clean primary endpoint is reached and confirmed by planimetry.

Secondary Outcome Measures

Name	Time	Method
Relative change in devitalized tissue and wound size at End of Treatment, compared to Baseline, assessed by planimetry	1 - 24 weeks	Assessed by planimetry

Trial Locations

Locations (7)

Wästerläkarna; 🇸🇪 Göteborg, Sweden

Vårdcentralen Tunafors; 🇸🇪 Eskilstuna, Sweden

Capio Lundby Sjukhus; 🇸🇪 Gothenburg, Sweden

Carlanderska Hospital; 🇸🇪 Göteborg, Sweden

Wetterhälsan Munksjöstaden; 🇸🇪 Jönköping, Sweden

Orthopedic Clinic Mölndal Hospital; 🇸🇪 Mölndal, Sweden

Framtidens vårdavdelning; 🇸🇪 Trelleborg, Sweden